A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

This study is testing a drug called belzupacap sarotalocan (AU-011) for bladder cancer that has not invaded the muscle wall (called non-muscle-invasive bladder cancer, or NMIBC). The drug is activated by laser light during a procedure called a cystoscopy (a camera exam of the bladder), targeting tumors from the inside. **You may be eligible if...** - You have been diagnosed with non-muscle-invasive bladder cancer (NMIBC) confirmed by biopsy - Your cancer type fits one of the study cohorts: intermediate-risk (such as multiple small tumors or a single large low-grade tumor) or high-risk (high-grade or T1 stage) - You may have had prior BCG treatment (a standard bladder cancer therapy) but it didn't work, you couldn't tolerate it, or you haven't had it yet **You may NOT be eligible if...** - Your cancer is BCG-refractory (meaning it kept growing despite a full course of BCG treatment) - Your cancer has invaded the muscle layer of the bladder - You have disease outside the bladder Talk to your doctor to see if this trial is right for you.